Quarterly report pursuant to Section 13 or 15(d)

License Revenue (Tables)

v3.22.1
License Revenue (Tables)
3 Months Ended
Mar. 31, 2022
Product Revenue  
Schedule of license revenue

Three Months Ended

March 31, 

2022

2021

Pharmbio Korea Inc.

$

20

$

Jiangsu Nhwa Pharmaceutical Co. Ltd.

Total license revenues

$

20

$